A5075113407- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Urological Disorders and Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Kidney Stones and Urolithiasis Treatments
- Cancer Immunotherapy and Biomarkers
- Urinary Bladder and Prostate Research
- Pediatric Urology and Nephrology Studies
- Cancer, Lipids, and Metabolism
- Multiple and Secondary Primary Cancers
- Renal and related cancers
- Urologic and reproductive health conditions
- Ureteral procedures and complications
- Radiopharmaceutical Chemistry and Applications
- MRI in cancer diagnosis
- Esophageal Cancer Research and Treatment
- Ferroptosis and cancer prognosis
- Pelvic floor disorders treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Pancreatic and Hepatic Oncology Research
- Ovarian cancer diagnosis and treatment
- Peptidase Inhibition and Analysis
Medical University of Vienna
2016-2025
Karl Landsteiner Society
2017-2025
Vienna General Hospital
2013-2025
Universitätsklinikum St. Pölten
2011-2025
Karl Landsteiner University of Health Sciences
2025
European Association of Urology
2024
Comprehensive Cancer Center Vienna
2014-2023
Klinik und Poliklinik für Urologie
2023
University of Vienna
2004-2023
Bundeswehrzentralkrankenhaus Koblenz
2021
No AccessJournal of UrologyAdult Urology1 May 2013Prediction Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development an Optimized Postoperative Nomogram Using Decision Curve Analysis Morgan Rouprêt, Vincent Hupertan, Thomas Seisen, Pierre Colin, Evanguelos Xylinas, David R. Yates, Harun Fajkovic, Yair Lotan, Jay D. Raman, Richard Zigeuner, Mesut Remzi, Christian Bolenz, Giacomo Novara, Wassim Kassouf, Adil Ouzzane, François Rozet, Olivier...
To evaluate the diagnostic performance of [68Ga]Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA-PET) in early detection metastases patients with biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically non-metastatic prostate cancer, to compare it CT/MRI alone and assess its impact on further therapeutic decisions. We retrospectively assessed 117 consecutive hormone-naïve BCR who had 68Ga-PSMA PET/CT (n = 46) or PET/MRI 71) between May 2014 January 2017....
What's known on the subject? and What does study add? Little is association between obesity urothelial carcinoma of bladder ( UCB ). Most studies have shown that higher body mass index BMI ) associated with rates perioperative complications. Only one specifically investigated cancer‐specific outcomes reported no significant disease‐specific survival in patients treated radical cystectomy. However, was limited by its small sample size a high rate preoperative therapies. In contrast to only...
Abstract Background To assess which parameters of [ 68 Ga]Ga‐PSMA‐11 positron emission tomography (PSMA‐PET) predict response to systemic therapies in metastatic (m) castration‐resistant prostate cancer (CRPC). In addition, investigate these factors are associated with overall survival (OS). Methods We retrospectively assessed the following PSMA‐PET 43 patients before and after for mCRPC: PSMA total tumor volume (TTV), mean standardized uptake value (SUVmean), SUVmax, SUVpeak....
What's known on the subject? and What does study add? Whereas open nephron‐sparing surgery ( NSS ) represents ‘gold standard’ in surgical therapy of T 1 renal tumours, with advances laparoscopic surgery, refinement intracorporeal suturing availability haemosealant substances, approach to is increasingly used. Laparoscopic partial nephrectomy LPN ), however, currently performed just a few high‐volume reference centres, its diffusion has been limited by steep learning curve. Conversely,...
To assess the association between diabetes mellitus (DM) and metformin use with prognosis outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients NMIBC treated at four institutions 1996 2007. Cox regression models were used to analyse DM disease recurrence, progression, cancer-specific mortality any-cause mortality.Of patients, 125 (11.1%) had 43 (3.8%) metformin. Within a median (interquartile range) follow-up 64 (22-106)...